Bivalirudin

Bivalirudin is a synthetic 20-amino acid peptide that functions as a direct, specific, and reversible inhibitor of thrombin (Factor IIa), the central enzyme in the coagulation cascade. The drug was designed based on the structure of hirudin, a naturally occurring anticoagulant found in the saliva of the medicinal leech (Hirudo medicinalis). Bivalirudin binds to both the active catalytic site and the anion-binding exosite 1 of thrombin, providing potent anticoagulation.

A unique feature of bivalirudin is that once bound to thrombin, the drug is slowly cleaved by thrombin itself at the N-terminal end, restoring thrombin's catalytic activity. This creates a "self-regulated" anticoagulant effect with a predictable and relatively short duration of action (half-life of approximately 25 minutes in patients with normal renal function). This property provides a more controllable and predictable anticoagulation profile compared to unfractionated heparin.

Bivalirudin's primary clinical application is as an anticoagulant during percutaneous coronary interventions (PCI), where it has been studied extensively as an alternative to heparin (with or without GP IIb/IIIa inhibitors). The landmark HORIZONS-AMI trial demonstrated that bivalirudin monotherapy during primary PCI for ST-elevation myocardial infarction (STEMI) significantly reduced major bleeding and all-cause mortality compared to heparin plus GP IIb/IIIa inhibitor, establishing bivalirudin as a preferred anticoagulant strategy in many catheterization laboratories.

Bivalirudin offers particular advantages in patients with heparin-induced thrombocytopenia (HIT), a potentially life-threatening immune-mediated reaction to heparin, as it provides effective anticoagulation without cross-reactivity with HIT antibodies. Its predictable pharmacokinetics and the lack of need for antithrombin as a cofactor (unlike heparin) are additional advantages.